MedPath

Tagged News

Lila Biologics Partners with Eli Lilly for AI-Driven Radioligand Therapy Development

OncologyAI
  • Lila Biologics announced a global licensing and multi-target research collaboration with Eli Lilly focused on discovering and developing novel radioligand therapies for solid tumor imaging and treatment.
  • The Seattle-based biotech company launched two AI/ML-powered protein therapeutic platforms: a targeted radiotherapy platform for oncology and a long-acting injectables platform for non-oncology diseases.
  • Under the collaboration agreement, Lila will design precision-targeted proteins through development candidate selection, while Lilly will handle IND-enabling studies, clinical development, and commercialization.
  • The company spun out from Nobel Laureate David Baker's lab at the University of Washington's Institute for Protein Design and utilizes proprietary LILADD™ framework for rapid protein optimization.

SOPHiA GENETICS Partners with Belgium's Jessa Ziekenhuis to Advance Precision Oncology Through AI-Driven Genomic Platform

AI
  • SOPHiA GENETICS has announced a strategic collaboration with Jessa Ziekenhuis, one of Belgium's largest healthcare institutions serving over 530,000 patients, to implement the SOPHiA DDM™ platform for unified next-generation sequencing workflows.
  • The partnership will deploy six specialized applications for solid tumors, hematologic malignancies, and liquid biopsy analysis, with expected efficiency gains including 30-50% reduction in hands-on time and up to 25% cost savings.
  • The collaboration establishes the Bridge Consortium with AZ Delta hospital to share NovaSeq sequencing capacity, demonstrating a novel model for resource optimization in precision oncology across European healthcare networks.

Predictive Oncology Partners with Every Cure to Accelerate AI-Driven Drug Repurposing for Cancer Treatment

AIOncology
  • Predictive Oncology and Every Cure have formed a strategic collaboration to identify and prioritize existing drugs for repurposing in cancer treatment using AI-driven platforms.
  • The partnership leverages Predictive Oncology's biobank of over 150,000 tumor samples across more than 130 cancer types and their PEDAL AI platform, which predicts tumor drug response with 92% accuracy.
  • Every Cure's AI models utilize knowledge graphs, large language models, and real-world medical data to identify potential connections between existing drugs and diseases for rigorous evaluation.
  • The collaboration aims to accelerate the delivery of life-saving treatments to cancer patients worldwide by combining machine learning capabilities with extensive tumor sample databases.

Ketryx Secures $39M Series B to Accelerate AI-Powered Compliance Platform for Life Sciences

AI
  • Ketryx, an AI-powered compliance platform for life sciences companies, raised $39 million in Series B funding led by Transformation Capital to advance regulatory workflows and product development.
  • The platform automates validation, traceability, and FDA/EU MDR-ready documentation, with customers reporting up to 90% reduction in documentation time and over 10x faster release cycles.
  • Three of the top five global medtech companies and several Fortune 500 organizations already use Ketryx's enterprise platform, positioning it as key AI infrastructure for regulated industries.
  • The funding brings total investment to over $55 million and will support global expansion, product development, and rapid hiring in Boston and Austria offices.

Rapafusyn Pharmaceuticals Secures $44 Million Series A to Advance Non-Degrading Molecular Glue Platform

Drug DiscoveryAI
  • Rapafusyn Pharmaceuticals closed an over-subscribed $44 million Series A financing round, adding BioTrack Capital and Yonjin Capital as new investors alongside existing backers.
  • The company's RapaGlue™ platform creates non-degrading molecular glues that can target previously undruggable proteins across oncology, immunology, renal and pain disease areas.
  • Rapafusyn's lead program, a selective ENT1 inhibitor for renal disease, is advancing toward IND-enabling studies after demonstrating compelling activity in disease models.
  • The platform leverages machine learning and AI methods with a DNA-encoded library of over 8 billion molecular glues to achieve industry-leading success rates in drug discovery.

Enveda Biosciences Raises $150M Series D to Advance AI-Driven Drug Discovery Platform

AIDrug Discovery
  • Enveda Biosciences secured $150 million in Series D funding led by Premji Invest to advance its AI-powered drug discovery platform that mines natural molecules for therapeutic development.
  • The company has initiated Phase 1b testing of its lead candidate ENV-294 in atopic dermatitis, with the small molecule representing a completely new chemical class showing kinase inhibitor-like and steroid-like behavior.
  • Enveda's pipeline includes multiple programs targeting inflammatory bowel disease, fibrotic conditions, and obesity, with several investigational new drug applications planned for the coming year.
  • Former Pfizer Chief Scientific Officer Mikael Dolsten will join the company's board of directors as it aims to tackle large-market diseases driven by multiple mechanisms.

Orbital Therapeutics Appoints Adam Raff as Senior VP to Advance RNA Medicine Platform Toward Clinical Trials

AI
  • Orbital Therapeutics has appointed Adam Raff, M.D., Ph.D., as Senior Vice President of Clinical Development to oversee clinical and regulatory strategy for the company's RNA medicine portfolio.
  • Dr. Raff will lead the advancement of OTX-201, a potential best-in-class program targeting B cell-driven autoimmune diseases, with clinical development expected to begin in the first half of 2026.
  • The appointment comes as Orbital progresses OTX-201 through IND-enabling studies following encouraging preclinical data, positioning the company to translate its innovative RNA platform into clinical applications.
  • Dr. Raff brings over a decade of drug development experience, including leadership roles at Montai Therapeutics, EQRx, and LEO Pharma, with extensive expertise in immunology and inflammatory disorders.

MultiOmic Health Partners with Serbia's BIO4 Campus to Develop AI-Driven Precision Medicine for Cardio-Renal-Metabolic Diseases

Precision MedicineAI
  • MultiOmic Health Limited and BIO4 Campus signed a memorandum of understanding to collaborate on precision medicine research focused on cardio-renal-metabolic diseases using AI and multi-omics approaches.
  • The partnership will develop AI-enabled tools to stratify patient endotypes at earlier disease stages and identify patient-specific drug targets through integrative analysis of genetics, epigenetics, transcriptomics, proteomics and metabolomics.
  • The collaboration aims to create AI-based Software as Medical Device and In Vitro Diagnostic products to optimize patient care pathways and enable more personalized treatment approaches.
  • BIO4 Campus brings together over 1,000 PhD scientists and 300 laboratories from 16 institutions, providing a robust research infrastructure for advancing Serbia's bioeconomy ecosystem.

Reveal HealthTech Secures $7.2M Series A to Advance AI-Driven Healthcare Solutions

AI
  • Reveal HealthTech raised $7.2 million in Series A funding led by Leo Capital to expand its AI transformation services for U.S. healthcare and life sciences companies.
  • The company's flagship products include BioCanvas for accelerating clinical trial recruitment and Prism AI for workflow automation in healthcare operations.
  • A recent deployment for a $40 billion U.S. medical device leader demonstrated improved patient adherence through AI-driven data integration.
  • The funding will support expansion of capabilities, strengthening of sales networks, and broader reach to healthcare and life sciences organizations worldwide.

Gilead Sciences Breaks Ground on $32 Billion AI-Enabled Biologics Development Center

AI
  • Gilead Sciences has broken ground on a new 180,000 square foot Pharmaceutical Development and Manufacturing Technical Development Center at its Foster City headquarters as part of a $32 billion U.S. investment through 2030.
  • The five-story facility will feature digitally enabled systems, autonomous robotics, and real-time digital monitoring, making it one of the most AI-enabled centers in the biopharmaceutical industry.
  • The investment is projected to generate more than $43 billion in economic value nationwide and create over 3,000 direct and indirect high-quality jobs while strengthening Gilead's biologics capabilities across virology, oncology, and inflammation.
  • The new center will accelerate technology transfer and support advancement of next-generation biologics across Gilead's pipeline, serving as a hub for innovation and collaboration between technical development and manufacturing teams.

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

© 2025 MedPath, Inc. All rights reserved.